IDEXX Laboratories (NASDAQ:IDXX) Posts Quarterly Earnings Results, Beats Expectations By $0.33 EPS

IDEXX Laboratories (NASDAQ:IDXX) announced its earnings results on Tuesday. The company reported $4.27 EPS for the quarter, beating the consensus estimate of $3.94 by $0.33, Zacks reports. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.During the same quarter in the prior year, the company posted $3.50 EPS. The company’s revenue for the quarter was up 9.7% on a year-over-year basis. IDEXX Laboratories updated its FY 2026 guidance to 14.690-14.940 EPS.

Here are the key takeaways from IDEXX Laboratories’ conference call:

• Strong second-quarter performance: Revenue grew 10% reported and 9% organically, while comparable EPS increased 15% to $4.27. IDEXX raised its full-year revenue outlook to $4.70 billion–$4.745 billion and EPS outlook to $14.69–$14.94.
• CAG Diagnostics recurring revenue grew 10.3% organically, including nearly 10% growth in the U.S. and nearly 12% internationally, driven by testing volumes, customer additions, instrument placements and higher utilization.
• Innovation momentum remained strong, with 1,602 inVue Dx placements in the quarter and 2,700 year-to-date, keeping the company on pace for its 5,500-unit annual goal. The controlled rollout of inVue Dx FNA is expanding in the third quarter, with broad availability planned by year-end, while Cancer Dx surpassed 10,000 ordering clinics.
• U.S. same-store clinical visits declined 1.3%, with wellness visits down nearly 3%, and IDEXX expects a similar approximately 1.5% decline in the second half. Management cited consumer economic pressure and slower pet adoption trends as ongoing constraints.
• Comparable operating margin expanded 110 basis points to approximately 35% in the second quarter, but IDEXX plans additional commercial, R&D, IT and AI investments in the second half. The company also expects foreign exchange to create a $15 million full-year revenue headwind, partly offsetting operational improvements.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX traded up $17.79 during mid-day trading on Tuesday, hitting $585.63. The company had a trading volume of 416,810 shares, compared to its average volume of 577,771. IDEXX Laboratories has a 12 month low of $518.55 and a 12 month high of $769.98. The stock has a market cap of $46.19 billion, a price-to-earnings ratio of 43.23, a PEG ratio of 3.06 and a beta of 1.54. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The firm’s 50 day simple moving average is $557.53 and its two-hundred day simple moving average is $588.43.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on IDXX shares. Citigroup initiated coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target on the stock. UBS Group reduced their target price on IDEXX Laboratories from $640.00 to $620.00 and set a “neutral” rating on the stock in a report on Monday, July 27th. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Finally, Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, July 29th. Six analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $749.00.

Hedge Funds Weigh In On IDEXX Laboratories

Several hedge funds and other institutional investors have recently modified their holdings of IDXX. Empowered Funds LLC increased its stake in shares of IDEXX Laboratories by 6.6% in the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after purchasing an additional 95 shares during the period. Sivia Capital Partners LLC acquired a new position in shares of IDEXX Laboratories during the second quarter valued at $265,000. Jump Financial LLC increased its holdings in shares of IDEXX Laboratories by 1,006.4% during the second quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock valued at $2,967,000 after purchasing an additional 5,032 shares during the period. Cary Street Partners Financial LLC bought a new stake in shares of IDEXX Laboratories during the second quarter valued at about $164,000. Finally, Sei Investments Co. grew its position in IDEXX Laboratories by 218.7% in the 2nd quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock valued at $64,678,000 after buying an additional 82,755 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.